Radiopharmaceutical Manufacturing and Formulation

This contract involves the manufacture, sterile formulation, and quality release of five F-18 labeled PET radiopharmaceuticals: Amyvid, Tauvid, Cerianna, Posluma, and Axumin. All activities are required to comply with current Good Manufacturing Practices (cGMP) and FDA regulatory standards, ensuring high-quality production suited for medical diagnostic applications. The work is to be performed as a subcontract for the Department of Veterans Affairs under the 247-NETWORK Contract Office 7 (36C247). The contract specifically targets the production location in Decatur, with a focus on the NAICS code 325412, which pertains to pharmaceutical preparation manufacturing. The solicitation for this contract was posted on June 10, 2026, with a response deadline of June 15, 2026, at midday. While details such as the type of set-aside or specific point of contact were not provided, the overall scope emphasizes the critical role of manufacturing compliant radiopharmaceuticals for diagnostic imaging. This contract supports the delivery of essential medical imaging agents used in brain and prostate cancer diagnostics, serving the needs of veterans and the wider healthcare system.